13F Holdings
中文EN

BKHA Black Hawk Acquisition Corp

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2000775 · Fiscal year ends 11/30

Financial factors as of 2026-08-31 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-37.7%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA5.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets18.2%
Debt / equity—
Current ratio0.02x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.43x
Accruals ratio7.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-11-30FY20242024-11-30
Income statement
Revenue——
SG&A expense$795,510$492,131
Operating income-$915,510-$576,076
Interest expense$15,454—
Net income$1.33M$1.92M
EPS (diluted)——
Banking
Net interest income$2.26M$2.48M
Deposits$690,000$690,000
Balance sheet
Cash & equivalents$0$264,842
Current assets$50,790$314,071
Intangibles$5.00M—
Total assets$23.88M$72.14M
Current liabilities$1.48M$70,978
Total liabilities$3.90M$2.49M
Shareholders' equity-$3.85M-$2.17M
Cash flow statement
Operating cash flow-$650,321-$553,665
Investing cash flow$50.26M-$69.34M
Financing cash flow-$49.84M$70.04M

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.